Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.

ABSTRACT: Successful efforts to control infectious diseases have often required the use of effective vaccines. The current global strategy for control of malaria, including elimination and eradication will also benefit from the development of an effective vaccine that interrupts malaria transmission. To this end, a vaccine that disrupts malaria transmission within the mosquito host has been investigated for several decades targeting a 25 kDa ookinete specific surface protein, identified as Pfs25. Phase 1 human trial results using a recombinant Pfs25H/Montanide ISA51 formulation demonstrated that human Pfs25 specific antibodies block parasite infectivity to mosquitoes; however, the extent of blocking was likely insufficient for an effective transmission blocking vaccine. To overcome the poor immunoge

SUBMITTER: Shimp RL 

PROVIDER: S-EPMC3683851 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature